Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression.

Jin X, Ding D, Yan Y, Li H, Wang B, Ma L, Ye Z, Ma T, Wu Q, Rodrigues DN, Kohli M, Jimenez R, Wang L, Goodrich DW, de Bono J, Dong H, Wu H, Zhu R, Huang H.

Mol Cell. 2019 Jan 3;73(1):22-35.e6. doi: 10.1016/j.molcel.2018.10.034. Epub 2018 Dec 6.

PMID:
30527665
2.

Spectroscopic and theoretical studies of some 2‑(methoxy)‑2‑[(4‑substituted)‑phenylsulfanyl]‑(4'‑substituted) acetophenones.

Traesel HJ, Olivato PR, Rodrigues DNS, Valença J, Rodrigues A, Zukerman-Schpector J, Colle MD.

Spectrochim Acta A Mol Biomol Spectrosc. 2019 Mar 5;210:82-97. doi: 10.1016/j.saa.2018.11.010. Epub 2018 Nov 12.

PMID:
30447629
3.

Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.

Rodrigues DN, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, Margolis C, Miao D, Miranda S, Dolling D, Clarke M, Bertan C, Crespo M, Boysen G, Ferreira A, Sharp A, Figueiredo I, Keliher D, Aldubayan S, Burke KP, Sumanasuriya S, Fontes MS, Bianchini D, Zafeiriou Z, Mendes LST, Mouw K, Schweizer MT, Pritchard CC, Salipante S, Taplin ME, Beltran H, Rubin MA, Cieslik M, Robinson D, Heath E, Schultz N, Armenia J, Abida W, Scher H, Lord C, D'Andrea A, Sawyers CL, Chinnaiyan AM, Alimonti A, Nelson PS, Drake CG, Van Allen EM, de Bono JS.

J Clin Invest. 2018 Nov 1;128(11):5185. doi: 10.1172/JCI125184. Epub 2018 Nov 1. No abstract available.

4.

Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency.

Zafeiriou Z, Bianchini D, Chandler R, Rescigno P, Yuan W, Carreira S, Barrero M, Petremolo A, Miranda S, Riisnaes R, Rodrigues DN, Gurel B, Sumanasuriya S, Paschalis A, Sharp A, Mateo J, Tunariu N, Chinnaiyan AM, Pritchard CC, Kelly K, de Bono JS.

Eur Urol. 2019 Jan;75(1):184-192. doi: 10.1016/j.eururo.2018.09.048. Epub 2018 Oct 16.

5.

Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer.

Sharp A, Coleman I, Yuan W, Sprenger C, Dolling D, Rodrigues DN, Russo JW, Figueiredo I, Bertan C, Seed G, Riisnaes R, Uo T, Neeb A, Welti J, Morrissey C, Carreira S, Luo J, Nelson PS, Balk SP, True LD, de Bono JS, Plymate SR.

J Clin Invest. 2019 Jan 2;129(1):192-208. doi: 10.1172/JCI122819. Epub 2018 Nov 26.

6.

Microenvironmental niche divergence shapes BRCA1-dysregulated ovarian cancer morphological plasticity.

Heindl A, Khan AM, Rodrigues DN, Eason K, Sadanandam A, Orbegoso C, Punta M, Sottoriva A, Lise S, Banerjee S, Yuan Y.

Nat Commun. 2018 Sep 25;9(1):3917. doi: 10.1038/s41467-018-06130-3.

7.

Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis.

Lambros MB, Seed G, Sumanasuriya S, Gil V, Crespo M, Fontes M, Chandler R, Mehra N, Fowler G, Ebbs B, Flohr P, Miranda S, Yuan W, Mackay A, Ferreira A, Pereira R, Bertan C, Figueiredo I, Riisnaes R, Rodrigues DN, Sharp A, Goodall J, Boysen G, Carreira S, Bianchini D, Rescigno P, Zafeiriou Z, Hunt J, Moloney D, Hamilton L, Neves RP, Swennenhuis J, Andree K, Stoecklein NH, Terstappen LWMM, de Bono JS.

Clin Cancer Res. 2018 Nov 15;24(22):5635-5644. doi: 10.1158/1078-0432.CCR-18-0862. Epub 2018 Aug 9.

PMID:
30093450
8.

SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity.

Boysen G, Rodrigues DN, Rescigno P, Seed G, Dolling D, Riisnaes R, Crespo M, Zafeiriou Z, Sumanasuriya S, Bianchini D, Hunt J, Moloney D, Perez-Lopez R, Tunariu N, Miranda S, Figueiredo I, Ferreira A, Christova R, Gil V, Aziz S, Bertan C, de Oliveira FM, Atkin M, Clarke M, Goodall J, Sharp A, MacDonald T, Rubin MA, Yuan W, Barbieri CE, Carreira S, Mateo J, de Bono JS.

Clin Cancer Res. 2018 Nov 15;24(22):5585-5593. doi: 10.1158/1078-0432.CCR-18-0937. Epub 2018 Aug 1.

PMID:
30068710
9.

Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer.

Sundar R, Miranda S, Rodrigues DN, Chénard-Poirier M, Dolling D, Clarke M, Figueiredo I, Bertan C, Yuan W, Ferreira A, Chistova R, Boysen G, Perez DR, Tunariu N, Mateo J, Wotherspoon A, Chau I, Cunningham D, Valeri N, Carreira S, de Bono J.

Clin Colorectal Cancer. 2018 Dec;17(4):280-284. doi: 10.1016/j.clcc.2018.05.011. Epub 2018 Jun 8.

10.

Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss.

de Bono JS, De Giorgi U, Rodrigues DN, Massard C, Bracarda S, Font A, Arranz Arija JA, Shih KC, Radavoi GD, Xu N, Chan WY, Ma H, Gendreau S, Riisnaes R, Patel PH, Maslyar DJ, Jinga V.

Clin Cancer Res. 2019 Feb 1;25(3):928-936. doi: 10.1158/1078-0432.CCR-18-0981. Epub 2018 Jul 23.

PMID:
30037818
11.

Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers.

Rescigno P, Lorente D, Dolling D, Ferraldeschi R, Rodrigues DN, Riisnaes R, Miranda S, Bianchini D, Zafeiriou Z, Sideris S, Ferreira A, Figueiredo I, Sumanasuriya S, Mateo J, Perez-Lopez R, Sharp A, Tunariu N, de Bono JS.

Eur Urol Oncol. 2018 May;1(1):71-77. doi: 10.1016/j.euo.2018.02.006.

12.

BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer.

Li X, Baek G, Ramanand SG, Sharp A, Gao Y, Yuan W, Welti J, Rodrigues DN, Dolling D, Figueiredo I, Sumanasuriya S, Crespo M, Aslam A, Li R, Yin Y, Mukherjee B, Kanchwala M, Hughes AM, Halsey WS, Chiang CM, Xing C, Raj GV, Burma S, de Bono J, Mani RS.

Cell Rep. 2018 Jan 16;22(3):796-808. doi: 10.1016/j.celrep.2017.12.078.

13.

Non-Invasive Prostate Cancer Characterization with Diffusion-Weighted MRI: Insight from In silico Studies of a Transgenic Mouse Model.

Hill DK, Heindl A, Zormpas-Petridis K, Collins DJ, Euceda LR, Rodrigues DN, Moestue SA, Jamin Y, Koh DM, Yuan Y, Bathen TF, Leach MO, Blackledge MD.

Front Oncol. 2017 Dec 1;7:290. doi: 10.3389/fonc.2017.00290. eCollection 2017.

14.

Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification.

Seed G, Yuan W, Mateo J, Carreira S, Bertan C, Lambros M, Boysen G, Ferraldeschi R, Miranda S, Figueiredo I, Riisnaes R, Crespo M, Rodrigues DN, Talevich E, Robinson DR, Kunju LP, Wu YM, Lonigro R, Sandhu S, Chinnaiyan M, de Bono JS.

Clin Cancer Res. 2017 Oct 15;23(20):6070-6077. doi: 10.1158/1078-0432.CCR-17-0972. Epub 2017 Jul 27. Erratum in: Clin Cancer Res. 2018 May 1;24(9):2234.

15.

Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.

Goodall J, Mateo J, Yuan W, Mossop H, Porta N, Miranda S, Perez-Lopez R, Dolling D, Robinson DR, Sandhu S, Fowler G, Ebbs B, Flohr P, Seed G, Rodrigues DN, Boysen G, Bertan C, Atkin M, Clarke M, Crespo M, Figueiredo I, Riisnaes R, Sumanasuriya S, Rescigno P, Zafeiriou Z, Sharp A, Tunariu N, Bianchini D, Gillman A, Lord CJ, Hall E, Chinnaiyan AM, Carreira S, de Bono JS; TOPARP-A investigators.

Cancer Discov. 2017 Sep;7(9):1006-1017. doi: 10.1158/2159-8290.CD-17-0261. Epub 2017 Apr 27.

16.

CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair.

Shenoy TR, Boysen G, Wang MY, Xu QZ, Guo W, Koh FM, Wang C, Zhang LZ, Wang Y, Gil V, Aziz S, Christova R, Rodrigues DN, Crespo M, Rescigno P, Tunariu N, Riisnaes R, Zafeiriou Z, Flohr P, Yuan W, Knight E, Swain A, Ramalho-Santos M, Xu DY, de Bono J, Wu H.

Ann Oncol. 2017 Jul 1;28(7):1495-1507. doi: 10.1093/annonc/mdx165.

17.

Disrupting Androgen Receptor Signaling Induces Snail-Mediated Epithelial-Mesenchymal Plasticity in Prostate Cancer.

Miao L, Yang L, Li R, Rodrigues DN, Crespo M, Hsieh JT, Tilley WD, de Bono J, Selth LA, Raj GV.

Cancer Res. 2017 Jun 1;77(11):3101-3112. doi: 10.1158/0008-5472.CAN-16-2169. Epub 2017 Mar 16.

18.

Circulating biomarkers of neuroendocrine prostate cancer: an unmet challenge.

Rescigno P, Rodrigues DN, de Bono JS.

BJU Int. 2017 Jan;119(1):3-4. doi: 10.1111/bju.13550. No abstract available.

19.

The molecular underpinnings of prostate cancer: impacts on management and pathology practice.

Rodrigues DN, Boysen G, Sumanasuriya S, Seed G, Marzo AM, de Bono J.

J Pathol. 2017 Jan;241(2):173-182. doi: 10.1002/path.4826. Epub 2016 Dec 1. Review.

PMID:
27753448
20.
21.

Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.

Welti J, Rodrigues DN, Sharp A, Sun S, Lorente D, Riisnaes R, Figueiredo I, Zafeiriou Z, Rescigno P, de Bono JS, Plymate SR.

Eur Urol. 2016 Oct;70(4):599-608. doi: 10.1016/j.eururo.2016.03.049. Epub 2016 Apr 23.

22.

Diffusion-weighted MRI for early detection and characterization of prostate cancer in the transgenic adenocarcinoma of the mouse prostate model.

Hill DK, Kim E, Teruel JR, Jamin Y, Widerøe M, Søgaard CD, Størkersen Ø, Rodrigues DN, Heindl A, Yuan Y, Bathen TF, Moestue SA.

J Magn Reson Imaging. 2016 May;43(5):1207-17. doi: 10.1002/jmri.25087. Epub 2015 Nov 11.

PMID:
26559017
23.

Crystal structure of 2-meth-oxy-2-[(4-meth-oxy-phen-yl)sulfan-yl]-1-phenyl-ethanone.

Caracelli I, Olivato PR, Traesel HJ, Valença J, Rodrigues DN, Tiekink ER.

Acta Crystallogr E Crystallogr Commun. 2015 Aug 15;71(Pt 9):o657-8. doi: 10.1107/S2056989015014565. eCollection 2015 Sep 1.

24.

PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients.

Punnoose EA, Ferraldeschi R, Szafer-Glusman E, Tucker EK, Mohan S, Flohr P, Riisnaes R, Miranda S, Figueiredo I, Rodrigues DN, Omlin A, Pezaro C, Zhu J, Amler L, Patel P, Yan Y, Bales N, Werner SL, Louw J, Pandita A, Marrinucci D, Attard G, de Bono J.

Br J Cancer. 2015 Oct 20;113(8):1225-33. doi: 10.1038/bjc.2015.332. Epub 2015 Sep 17.

25.

Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification.

Ng CK, Martelotto LG, Gauthier A, Wen HC, Piscuoglio S, Lim RS, Cowell CF, Wilkerson PM, Wai P, Rodrigues DN, Arnould L, Geyer FC, Bromberg SE, Lacroix-Triki M, Penault-Llorca F, Giard S, Sastre-Garau X, Natrajan R, Norton L, Cottu PH, Weigelt B, Vincent-Salomon A, Reis-Filho JS.

Genome Biol. 2015 May 22;16:107. doi: 10.1186/s13059-015-0657-6.

26.

Conformational Analysis and Electronic Interactions of Some 4'-Substituted-2-ethylthio-phenylacetates.

Rodrigues DN, Ducati LC, Olivato PR, Dal Colle M.

J Phys Chem A. 2015 Apr 23;119(16):3823-32. doi: 10.1021/acs.jpca.5b01531. Epub 2015 Apr 13.

PMID:
25839322
27.

Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents.

Crespo M, van Dalum G, Ferraldeschi R, Zafeiriou Z, Sideris S, Lorente D, Bianchini D, Rodrigues DN, Riisnaes R, Miranda S, Figueiredo I, Flohr P, Nowakowska K, de Bono JS, Terstappen LW, Attard G.

Br J Cancer. 2015 Mar 31;112(7):1166-74. doi: 10.1038/bjc.2015.63.

28.

Crystal structure of 2-meth-oxy-2-[(4-methyl-phen-yl)sulfan-yl]-1-phenyl-ethan-1-one.

Zukerman-Schpector J, Olivato PR, Traesel HJ, Valença J, Rodrigues DN, Tiekink ER.

Acta Crystallogr E Crystallogr Commun. 2015 Jan 1;71(Pt 1):o3-4. doi: 10.1107/S205698901402550X. eCollection 2015 Jan 1.

29.

Infiltrating S100A8+ myeloid cells promote metastatic spread of human breast cancer and predict poor clinical outcome.

Drews-Elger K, Iorns E, Dias A, Miller P, Ward TM, Dean S, Clarke J, Campion-Flora A, Rodrigues DN, Reis-Filho JS, Rae JM, Thomas D, Berry D, El-Ashry D, Lippman ME.

Breast Cancer Res Treat. 2014 Nov;148(1):41-59. doi: 10.1007/s10549-014-3122-4. Epub 2014 Oct 1.

PMID:
25270120
30.

Tumor clone dynamics in lethal prostate cancer.

Carreira S, Romanel A, Goodall J, Grist E, Ferraldeschi R, Miranda S, Prandi D, Lorente D, Frenel JS, Pezaro C, Omlin A, Rodrigues DN, Flohr P, Tunariu N, S de Bono J, Demichelis F, Attard G.

Sci Transl Med. 2014 Sep 17;6(254):254ra125. doi: 10.1126/scitranslmed.3009448.

31.

The promise of circulating tumor cell analysis in cancer management.

Mateo J, Gerlinger M, Rodrigues DN, de Bono JS.

Genome Biol. 2014 Aug 30;15(8):448. doi: 10.1186/s13059-014-0448-5. Review.

32.

Sarcomatoid carcinoma of the prostate: ERG fluorescence in-situ hybridization confirms epithelial origin.

Rodrigues DN, Hazell S, Miranda S, Crespo M, Fisher C, de Bono JS, Attard G.

Histopathology. 2015 May;66(6):898-901. doi: 10.1111/his.12493. Epub 2014 Nov 10. No abstract available.

PMID:
25041380
33.

Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail.

Ong M, Carreira S, Goodall J, Mateo J, Figueiredo I, Rodrigues DN, Perkins G, Seed G, Yap TA, Attard G, de Bono JS.

Br J Cancer. 2014 Aug 26;111(5):828-36. doi: 10.1038/bjc.2014.350. Epub 2014 Jul 1.

34.

EPO use by Brazilian athletes since 2000.

Almeida CB, Rodrigues DN, Barros EC.

Subst Use Misuse. 2014 Jul;49(9):1126-31. doi: 10.3109/10826084.2014.903748. Epub 2014 May 15.

PMID:
24832719
35.

Brazilian antidoping public policy.

Almeida CB, Rodrigues DN.

Subst Use Misuse. 2014 Jul;49(9):1146-51. doi: 10.3109/10826084.2014.903746. Epub 2014 May 6.

PMID:
24799072
36.

A short neuropsychological evaluation of patients with primary Sjögren's syndrome.

Rodrigues DN, Hora JS, Salgado MC, Paes RA, Vasconcelos CC, Landeira-Fernandez J, Alvarenga RM.

Arq Neuropsiquiatr. 2014 Jan;72(1):38-43. doi: 10.1590/0004-282X20130195.

37.

Visceral disease in castration-resistant prostate cancer.

Pezaro C, Omlin A, Lorente D, Rodrigues DN, Ferraldeschi R, Bianchini D, Mukherji D, Riisnaes R, Altavilla A, Crespo M, Tunariu N, de Bono J, Attard G.

Eur Urol. 2014 Feb;65(2):270-273. doi: 10.1016/j.eururo.2013.10.055. Epub 2013 Nov 22.

38.

Molecular pathology and prostate cancer therapeutics: from biology to bedside.

Rodrigues DN, Butler LM, Estelles DL, de Bono JS.

J Pathol. 2014 Jan;232(2):178-84. doi: 10.1002/path.4272. Review.

PMID:
24108540
39.

Spectroscopic and theoretical studies of some 3-(4'-substituted phenylsulfanyl)-1-methyl-2-piperidones.

Olivato PR, Santos JM, Contieri B, Cerqueira CR, Rodrigues DN, Vinhato E, Zukerman-Schpector J, Colle MD.

Molecules. 2013 Jun 27;18(7):7492-509. doi: 10.3390/molecules18077492.

40.

Mutation profiling of adenoid cystic carcinomas from multiple anatomical sites identifies mutations in the RAS pathway, but no KIT mutations.

Wetterskog D, Wilkerson PM, Rodrigues DN, Lambros MB, Fritchie K, Andersson MK, Natrajan R, Gauthier A, Di Palma S, Shousha S, Gatalica Z, Töpfer C, Vukovic V, A'Hern R, Weigelt B, Vincent-Salomon A, Stenman G, Rubin BP, Reis-Filho JS.

Histopathology. 2013 Mar;62(4):543-50. doi: 10.1111/his.12050. Epub 2013 Feb 12.

41.

Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer.

Ruark E, Snape K, Humburg P, Loveday C, Bajrami I, Brough R, Rodrigues DN, Renwick A, Seal S, Ramsay E, Duarte Sdel V, Rivas MA, Warren-Perry M, Zachariou A, Campion-Flora A, Hanks S, Murray A, Ansari Pour N, Douglas J, Gregory L, Rimmer A, Walker NM, Yang TP, Adlard JW, Barwell J, Berg J, Brady AF, Brewer C, Brice G, Chapman C, Cook J, Davidson R, Donaldson A, Douglas F, Eccles D, Evans DG, Greenhalgh L, Henderson A, Izatt L, Kumar A, Lalloo F, Miedzybrodzka Z, Morrison PJ, Paterson J, Porteous M, Rogers MT, Shanley S, Walker L, Gore M, Houlston R, Brown MA, Caufield MJ, Deloukas P, McCarthy MI, Todd JA; Breast and Ovarian Cancer Susceptibility Collaboration; Wellcome Trust Case Control Consortium, Turnbull C, Reis-Filho JS, Ashworth A, Antoniou AC, Lord CJ, Donnelly P, Rahman N.

Nature. 2013 Jan 17;493(7432):406-10. doi: 10.1038/nature11725. Epub 2012 Dec 16.

42.

Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor.

Barber LJ, Sandhu S, Chen L, Campbell J, Kozarewa I, Fenwick K, Assiotis I, Rodrigues DN, Reis Filho JS, Moreno V, Mateo J, Molife LR, De Bono J, Kaye S, Lord CJ, Ashworth A.

J Pathol. 2013 Feb;229(3):422-9. doi: 10.1002/path.4140.

PMID:
23165508
43.

Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection.

Hernandez L, Wilkerson PM, Lambros MB, Campion-Flora A, Rodrigues DN, Gauthier A, Cabral C, Pawar V, Mackay A, A'Hern R, Marchiò C, Palacios J, Natrajan R, Weigelt B, Reis-Filho JS.

J Pathol. 2012 May;227(1):42-52. doi: 10.1002/path.3990. Epub 2012 Mar 21.

44.

Molecular classification of estrogen receptor-positive/luminal breast cancers.

Geyer FC, Rodrigues DN, Weigelt B, Reis-Filho JS.

Adv Anat Pathol. 2012 Jan;19(1):39-53. doi: 10.1097/PAP.0b013e31823fafa0. Review.

PMID:
22156833
45.

Different cognitive profiles of Brazilian patients with relapsing-remitting and primary progressive multiple sclerosis.

Rodrigues DN, Paes RA, Vasconcelos CC, Landeira-Fernandez J, Alvarenga MP.

Arq Neuropsiquiatr. 2011 Aug;69(4):590-5.

46.

Sting_RDB: a relational database of structural parameters for protein analysis with support for data warehousing and data mining.

Oliveira SR, Almeida GV, Souza KR, Rodrigues DN, Kuser-Falcão PR, Yamagishi ME, Santos EH, Vieira FD, Jardine JG, Neshich G.

Genet Mol Res. 2007 Oct 5;6(4):911-22.

47.

The Star STING server: a multiplatform environment for protein structure analysis.

Neshich G, Mazoni I, Oliveira SR, Yamagishi ME, Kuser-Falcão PR, Borro LC, Morita DU, Souza KR, Almeida GV, Rodrigues DN, Jardine JG, Togawa RC, Mancini AL, Higa RH, Cruz SA, Vieira FD, Santos EH, Melo RC, Santoro MM.

Genet Mol Res. 2006 Dec 1;5(4):717-22.

48.

Prevalence of factor VII deficiency and molecular characterization of the F7 gene in Brazilian patients.

Rodrigues DN, Siqueira LH, Galizoni AM, Arruda VR, Annichino-Bizzacchi JM.

Blood Coagul Fibrinolysis. 2003 Apr;14(3):289-92.

PMID:
12695753

Supplemental Content

Loading ...
Support Center